Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Total Inventories : ¥457 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Total Inventories?

Shenzhenlubris Pharmaceuticals Co's total inventories for the quarter that ended in Mar. 2024 was ¥457 Mil. Shenzhenlubris Pharmaceuticals Co's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was ¥474 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Shenzhenlubris Pharmaceuticals Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was ¥0.71.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Shenzhenlubris Pharmaceuticals Co's Days Inventory for the three months ended in Mar. 2024 was 138.89.

Inventory Turnover measures how fast the company turns over its inventory within a year. Shenzhenlubris Pharmaceuticals Co's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.66.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Shenzhenlubris Pharmaceuticals Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.43.

Shenzhenlubris Pharmaceuticals Co Total Inventories Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Total Inventories Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

503.16

391.56

420.46

543.53

490.86

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															526.58	489.06	473.19	490.86	457.28

Shenzhenlubris Pharmaceuticals Co Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Shenzhenlubris Pharmaceuticals Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1594.423	+	0.75 * 470.274	+	0.5 * 457.277	-	1347.802
-	0	-	35.866)	/	1114.82
=	0.71

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Shenzhenlubris Pharmaceuticals Co's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	474.067	/	311.449	*	365 / 4
	=	138.89

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Shenzhenlubris Pharmaceuticals Co's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	311.449	/	474.067
	=	0.66

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Shenzhenlubris Pharmaceuticals Co's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	474.067	/	1090.969
	=	0.43

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Shenzhenlubris Pharmaceuticals Co Total Inventories Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines